Address
Email address
GaeaOÜ is an agile full-service CRO in Phase I – III, IIT in all of Europe, with partners in the USA and Australia Read more Agile full-service CRO Commissioned by Sponsors, Gaea Trial Acceleration identifies and addresses the issues at sites, that are blocking their enrolment Read more Trial Enrolment Accelerator The GaeaOÜ CEO will work in-house at a company to define the clinical strategy and execute it with the company’s choice of CRO Read more Clinical Trial Planning
Name
Gaea OÜ
Registry code
14474121
VAT number
EE102065613
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
20.04.2018 (6)
Financial year
01.01-31.12
Capital
2 500.00 €
Activity
74901 - Other professional, scientific and technical activities n.e.c.
408 980 €
-865 524 €
-212%
-
348 947 €
2
Submitted
No tax arrears
-248%
-189%
Owner | Representative | Beneficial owner | Roles | |
---|---|---|---|---|
Nigel Gerard Goodman 24.05.1952 (72) | 100% - 2 500.00 EUR | Board member | Direct ownership | Founder |
2019 22.06.2020 | 2020 09.03.2021 | 2021 07.03.2022 | 2022 06.02.2023 | 2023 19.02.2024 | |
---|---|---|---|---|---|
Total Revenue | 737 669 € | 2 347 885 € | 2 857 369 € | 1 475 826 € | 408 980 € |
Net profit (loss) for the period | 228 472 € | 438 325 € | 291 850 € | 368 852 € | -865 524 € |
Profit Margin | 31% | 19% | 10% | 25% | -212% |
Current Assets | 248 430 € | 1 211 404 € | 1 477 883 € | 1 380 152 € | 458 510 € |
Fixed Assets | 1 170 € | 30 117 € | 1 878 € | 175 € | 0 € |
Total Assets | 249 600 € | 1 241 521 € | 1 479 761 € | 1 380 327 € | 458 510 € |
Current Liabilities | 89 256 € | 660 452 € | 618 842 € | 165 856 € | 109 563 € |
Non Current Liabilities | - | - | - | - | - |
Total Liabilities | - | - | - | - | - |
Share Capital | - | - | - | - | - |
Equity | 160 344 € | 581 069 € | 860 919 € | 1 214 471 € | 348 947 € |
Employees | 1 | 1 | 2 | 2 | 2 |
Turnover | State taxes | Labor taxes and payments | Employees | |
---|---|---|---|---|
2024 Q1 | 277 010.76 € | 13 494.91 € | 11 959.95 € | - |
2023 Q4 | 318 004.39 € | 9 413.98 € | 8 874.05 € | 2 |
2023 Q3 | 269 677.24 € | 8 687.75 € | 9 038.04 € | 2 |
2023 Q2 | 253 007 € | 9 125.07 € | 8 961.13 € | 2 |
2023 Q1 | 176 156.58 € | 9 174.91 € | 9 535.31 € | 2 |
2022 Q4 | 458 277.78 € | 7 828.77 € | 7 365.03 € | 2 |
2022 Q3 | 698 901.7 € | 13 004.81 € | 12 737.22 € | 2 |
2022 Q2 | 707 305.04 € | 15 405.18 € | 10 848.16 € | 3 |
2022 Q1 | 720 609.19 € | 11 555.61 € | 9 667.23 € | 2 |
2021 Q4 | 1 393 067.88 € | 6 779.82 € | 10 686.87 € | 1 |
2021 Q3 | 1 152 499.24 € | - | 6 719.27 € | 1 |
2021 Q2 | 1 746 329.76 € | 4 413.48 € | 4 420.74 € | - |
2021 Q1 | 1 316 692.55 € | 3 975 € | 3 975 € | 1 |
2020 Q4 | 840 793.07 € | - | 3 975 € | 1 |
2020 Q3 | 548 745.15 € | 8 375 € | 3 975 € | 1 |
2020 Q2 | 514 314.3 € | 4 707.32 € | 4 680.97 € | 1 |
2020 Q1 | 874 047.22 € | 4 066.97 € | 3 982.45 € | 1 |